Thermo Fisher Scientific (TMO) FY2025 10-K Annual Report
Thermo Fisher Scientific (TMO) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Thermo Fisher Scientific FY2025 10-K Analysis
Business Overview
- • Core business: Life sciences tools & services conglomerate serving pharma/biotech, academic, industrial, and healthcare markets across four segments
- • Sept 2025 acquisition of Solventum's filtration/separation business (~$4.04B total acquisition spend in 2025) added bioproduction purification tech plus industrial filtration for battery, semiconductor, and medical device markets
- • Revenue $44.6B in 2025, up ~4% YoY; adjusted EPS $22.87 vs $21.86; Analytical Instruments segment margin compressed to 23.0% from 26.2% due to tariff impacts and FX headwinds
- • Total debt surged to $39.4B from $31.3B YoY, while cash jumped to $9.85B from $4.0B, reflecting $7.76B new debt issuance; $5B share buyback authorized Nov 2025
- • Federal government shutdown noted in Oct 2025 as a specific demand risk, with academic/government revenue explicitly declining due to U.S. policy uncertainty and China macro weakness
Management Discussion & Analysis
- • Revenue $44,556M, up ~3.9% YoY from $42,879M; Lab Products & Biopharma Services largest segment at $23,984M
- • GAAP operating margin 17.4% vs 17.1%; adjusted operating margin 22.7% vs 22.6%; driven by productivity gains offset by tariffs and mix
- • Best segment: Specialty Diagnostics margin 26.9% vs 25.7% (+1.2pt); worst: Analytical Instruments margin 23.0% vs 26.2% (-3.2pt) hit by tariffs
- • Free cash flow $6,337M vs $7,324M; capex $1,525M; buybacks $3.0B (5.8M shares); dividends $0.64B; total debt rose to $39.4B from $31.3B
- • 2026 capex guided $1.8B–$2.0B; GAAP tax rate 7%–9%; risks include academic/government spending hesitancy, China macro weakness, tariff impacts
Risk Factors
- • China regulations requiring local suppliers plus tariff volatility directly threaten international revenues, with currency translation adding $0.37B to 2025 revenues
- • Outstanding debt ~$39.38B with $5.00B revolving credit facility; covenant requires minimum 3.5:1.0 Consolidated Net Interest Coverage Ratio
- • Goodwill and indefinite-lived intangibles total ~$50.59B ($49.36B + $1.23B) on balance sheet, vulnerable to impairment if acquisitions underperform
- • FDA and DEA regulatory exposure: sole manufacturer for numerous pharma customers, meaning single negative regulatory event disrupts multiple downstream supply chains
- • Sole/limited-source suppliers for certain materials; no quick qualification of replacements if supplier exits, faces bankruptcy, or is hit by sanctions
Thermo Fisher Scientific FY2025 Key Financial MetricsXBRL
Revenue
$44.6B
▲ +3.9% YoY
Net Income
$6.7B
▲ +5.8% YoY
Operating Margin
17.4%
▲ +27bp YoY
Net Margin
15.0%
▲ +27bp YoY
ROE
12.6%
▼ -22bp YoY
Total Assets
$110.3B
▲ +13.4% YoY
EPS (Diluted)
$17.74
▲ +7.3% YoY
Operating Cash Flow
$7.8B
▼ -9.8% YoY
Source: XBRL data from Thermo Fisher Scientific FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Thermo Fisher Scientific
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.